Adaptive Biotechnologies Corporation - Common Stock (NQ:ADPT)

Total company profitability arrived early as MRD guidance moved higher.

Adaptive (ADPT) Q3 2026 Earnings Call Transcript ↗

November 05, 2026

Performance

52-Week Range 7.0% below 52-week high

29.94

12.0052W Low 32.2152W High

1 Week 7.0% below 1-week high

25.471W Low 32.211W High

Adaptive Biotechnologies Corporation - Common Stock (ADPT) traded between $12.00 and $32.21 over the past 52 weeks and last traded at $29.94, 7.0% below its 52-week high. Over the past week it ranged between $25.47 and $32.21.

Past 12 Months

+11.6%

+17.1%

+18.6%

+128.0%

+88.2%

+106.1%

1W +$3.11

1M +$4.37

3M +$4.69

6M +$16.81

YTD +$14.03

1Y +$15.41

ADPT was +106.1% over the past year, +128.0% over six months, +88.2% year to date, +11.6% in the last week.

12 Months vs Market

ADPT

+106.1%

DIA

+9.4%

SPY

+11.2%

QQQ

+11.1%

IWM

+15.9%

Over the past 12 months ADPT returned +106.1% versus DIA (Dow) +9.4%, SPY (S&P 500) +11.2%, QQQ (Nasdaq 100) +11.1% and IWM (Russell 2000) +15.9%.

Volume & Liquidity 0.00× 3-mo avg

Today 932 3-mo avg 2.2M

2.9M

2.2M

2.6M

YTD

2.3M

2.4M

ADPT most recently traded 932 shares against a 3-month average daily volume of 2.2M.

More News

Adaptive Biotechnologies Q3 Earnings Call Highlights ↗

November 04, 2026

Via MarketBeat

Adaptive Biotechnologies (NASDAQ:ADPT) Surges After Q2 Beat and Raised Guidance ↗

July 29, 2026

Via Chartmill

Adaptive Biotechnologies (NASDAQ:ADPT) Surges 6% on Q1 Beat and Raised MRD Guidance ↗

May 05, 2026

Via Chartmill

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

November 04, 2026

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

October 14, 2026

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

September 25, 2026

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

September 17, 2026

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 01, 2026

Adaptive Biotechnologies Q2 Earnings Call Highlights ↗

July 29, 2026

Via MarketBeat

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

July 29, 2026

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run ↗

July 12, 2026

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

July 09, 2026

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

June 17, 2026

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

June 15, 2026

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

June 15, 2026

What Does an Adaptive Biotech Insider's Sale of Nearly 40,000 Shares Mean for Investors? ↗

June 14, 2026

Adaptive Biotechnologies Highlights clonoSEQ Growth, 2026 Cash Flow Goal at Conference ↗

June 03, 2026

Via MarketBeat

At ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and Research

May 29, 2026

Harvest Investment Services Dumps 356,000 Adaptive Biotechnologies (ADPT) Shares Worth $5.7 Million ↗

May 26, 2026

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

May 21, 2026

Adaptive (ADPT) Q1 2026 Earnings Transcript ↗

May 06, 2026

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

May 05, 2026

Via Chartmill

Adaptive Biotechnologies Reports First Quarter 2026 Financial Results

May 05, 2026